WO1998050095A1 - Controlling gas or drug delivery to patient - Google Patents

Controlling gas or drug delivery to patient Download PDF

Info

Publication number
WO1998050095A1
WO1998050095A1 PCT/AU1997/000278 AU9700278W WO9850095A1 WO 1998050095 A1 WO1998050095 A1 WO 1998050095A1 AU 9700278 W AU9700278 W AU 9700278W WO 9850095 A1 WO9850095 A1 WO 9850095A1
Authority
WO
WIPO (PCT)
Prior art keywords
patient
sound
breathing
delivery
gas pressure
Prior art date
Application number
PCT/AU1997/000278
Other languages
French (fr)
Inventor
David Burton
Original Assignee
Compumedics Sleep Pty. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PCT/AU1997/000278 priority Critical patent/WO1998050095A1/en
Application filed by Compumedics Sleep Pty. Ltd. filed Critical Compumedics Sleep Pty. Ltd.
Priority to CNB971821534A priority patent/CN1154521C/en
Priority to EP97917938A priority patent/EP1007125B1/en
Priority to RU99125607/14A priority patent/RU2197281C2/en
Priority to IL13274897A priority patent/IL132748A/en
Priority to AU26269/97A priority patent/AU741637B2/en
Priority to DE69730748T priority patent/DE69730748T2/en
Priority to AT97917938T priority patent/ATE276001T1/en
Priority to KR10-1999-7010281A priority patent/KR100454157B1/en
Priority to JP54753098A priority patent/JP4090079B2/en
Priority to US09/423,380 priority patent/US6431171B1/en
Priority claimed from CNB971821534A external-priority patent/CN1154521C/en
Publication of WO1998050095A1 publication Critical patent/WO1998050095A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0001Details of inhalators; Constructional features thereof
    • A61M15/002Details of inhalators; Constructional features thereof with air flow regulating means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/021Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes operated by electrical means
    • A61M16/022Control means therefor
    • A61M16/024Control means therefor including calculation means, e.g. using a processor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00Measuring parameters of the user
    • A61M2230/04Heartbeat characteristics, e.g. ECG, blood pressure modulation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00Measuring parameters of the user
    • A61M2230/08Other bio-electrical signals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00Measuring parameters of the user
    • A61M2230/08Other bio-electrical signals
    • A61M2230/10Electroencephalographic signals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00Measuring parameters of the user
    • A61M2230/18Rapid eye-movements [REM]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00Measuring parameters of the user
    • A61M2230/20Blood composition characteristics
    • A61M2230/205Blood composition characteristics partial oxygen pressure (P-O2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00Measuring parameters of the user
    • A61M2230/60Muscle strain, i.e. measured on the user

Definitions

  • the present invention relates to apparatus for controlling gas delivery to a patient.
  • the apparatus of the present invention is related to apparatus disclosed in applicant's copending PCT application AU96/00679 filed 31 October 1996 and in AU Patent 632932 entitled "Analysis System for physiological variables", the disclosures of which are incorporated herein by cross reference.
  • the apparatus of the present invention may provide a diagnostic and/or a therapeutic function.
  • the diagnostic function may include monitoring and/or diagnosis of physiological variables associated with the patient.
  • the therapeutic function may include application of controlled gas delivery to the patient.
  • the diagnostic and therapeutic functions may be performed in a single device having integrated functions or it may be performed via two or more separate devices.
  • the apparatus of the present invention is particularly useful for investigation, diagnosis and treatment of sleep, respiratory and sleep related respiratory disorders, sleep propensity, fatigue and asthma and will be described herein in that context. Nevertheless it is to be appreciated that it is not thereby limited to such applications.
  • the apparatus of the present invention has been developed for, but is not limited to monitoring, analysing, storing, controlling and networking physiological variables.
  • the aforementioned "controlling of physiological variables” includes controlling the gas delivery to a patient.
  • This gas can be but is not limited to air as used in a CPAP (Continuous Positive Air Pressure) application, or one of the many variations of positive air pressure delivery to a patient known in the art.
  • CPAP Continuous Positive Air Pressure
  • the monitored physiological variables and events can include one or more channels of each of the following signal types:
  • CPAP mask sound monitoring for patients breathing sounds within CPAP mask.
  • Muscle function/Electro-myogram other EMG reflecting muscle and nerve activity either by invasive or non-invasive monitoring
  • CPAP mask temperature (monitoring of CPAP mask air temperature for breathing activity and airflow of patient) • Status of lights
  • Mattress Device monitoring of patient sleep state and respiratory parameters by using a mattress sensor device.
  • the matress device can be used to monitor a patient's electro-oculogram, sleep state, arousals, position, electrocardiogram.
  • SCSB Static Charge-sensitive Bed
  • PVDF - piezoelectric plastic polyvinylidene fluoride
  • the present invention allows one or more channels of patient variables and/or events to be monitored, processed and recorded, while at the same time allowing precise data interconnection with a remote site.
  • This remote site can view, process or record the real-time patient data.
  • the communication link can take the form of a range of transmission media, including but not limited to wireless interconnection such as spread spectrum transmission wireless LAN.
  • apparatus for controlling gas delivery to a patient said delivery being adapted to maintain effective respiratory function
  • said apparatus including: means for monitoring one or more physiological variables associated with said patient; means for deriving from said one or more variables, data representing a respiratory state associated with said patient; and means for determining from said data, a gas pressure value which substantially prevents a deterioration in said state.
  • the monitoring means may include means such as a plurality of sensors and/or transducers for acquiring and monitoring variables representing physiological states associated with the patient.
  • the physiological variables can include respiratory effort, breathing airflow, oximetry and/or sound.
  • the monitoring means includes an air pressure wave or sound/acoustic vibration transducer to monitor breathing sound and/or air pressure waves associated with the patient's respiratory function.
  • the air or sound pressure wave transducer may include a sound microphone, air pressure sensor, air flow sensor or similar device.
  • the air/sound pressure wave transducer may be located near the patient such as being incorporated in the nasal or nasal and oral mask used to deliver gas to the patient, or at any other location suitable for monitoring patient airflow and/or sound.
  • the apparatus may include other respiratory parameters input for the purpose of monitoring and detection of respiratory effort and/or respiratory disorders.
  • the or each sensor and/or transducer may generate an analog signal representative of variables being monitored.
  • the monitoring means may include means for amplifying and/or performing analog processing on the analog signal. The latter may perform filtering and/or other wave shaping functions.
  • the processed signal may be fed to an analog to digital converter to convert the or each analog signal to a corresponding digital signal.
  • the or each digital signal may be fed to a digital processor such a microprocessor or microcomputer.
  • the digital processor may include software for deriving from the or each digital signal data representing the patients respiratory state.
  • the software may include means such as an algorithm for determining from the data a gas pressure value which substantially prevents a deterioration of the respiratory state.
  • the algorithm may be adapted to generate a gas pressure signal which is substantially 180° out of phase relative to the phase of the patient breathing air flow and/or sound together with an option of a further gas pressure signal which changes relatively slowly when compared to the out of phase signal.
  • the latter may be used to control delivery of gas to the patient to cancel out or substantially compensate the effects of a breathing disorder.
  • the software may be adapted to activate delivery of a drug such as ventilum. This may circumvent what may otherwise be a fatal or severe asthma attack.
  • the software may additionally be adapted to determine quantity requirements of the drug. The latter may be based on the patients history and the extent to which the disorder fails to respond to gas pressure treatment.
  • Figure 1 shows a block diagram of one form of gas delivery apparatus according to the present invention
  • Figs. 1 A to 1 F show waveforms associated with the apparatus of Fig. 1 ;
  • Fig. 2 shows an overview of system software which may be used in conjunction with the apparatus shown in Fig. 1 ;
  • Figs. 3, 3A and 3B show a flow diagram of the sound and respiratory event detector /recorder
  • Figs. 4 and 4A show a flow diagram of the respiratory acoustic cancellation feedback servo system
  • Fig. 5 shows one form of gas delivery system modified in accordance with the principles of the present invention.
  • microphone 2 picks up sound from patient 1 and converts this to an electrical signal.
  • the electrical signal from microphone 2 is analog in nature and is passed to signal amplifying and processing module 3.
  • Amplifying and processing module 3 amplifies the analog signal and performs filtering and/or wave shaping as required.
  • the analog signal then passes to module 5.
  • Module 5 also receives data from one or more sensors and/or transducers adapted to monitor a range of physiological variables associated with patient 1 such as respiratory effort, respiratory airflow, patient oxygen saturation, brain waves (EEG), heart beat (ECG), eye movement (EOG) muscle function (EMG), patient position and the like.
  • EEG brain waves
  • ECG heart beat
  • EOG eye movement
  • EMG eye movement muscle function
  • Module 5 includes one or more analog to digital convertors and a digital central processing unit (CPU) such as a microprocessor or microcontroller.
  • the CPU is loaded with software including one or more processing algorithms for generating, inter alia, a gas control signal.
  • the gas control signal may be adapted to produce a constant or varying gas pressure and/or air flow as required to compensate a prevailing respiratory disorder.
  • the gas control signal is fed to pressure transducer 6 to produce a gas pressure which is of a similar frequency but is substantially 180° out of phase relative to the phase of the respiratory signal picked up by microphone 2.
  • the antiphase gas pressure produced by pressure transducer 6 is fed to the patient 1 via a conduit such as a plastics tube and may be applied via the nasal or nasal and oral mask to substantially cancell or compensate the effect of the prevailing breathing disorder.
  • Pressure transducer 6 may include a pressure valve for controlling gas pressure or an acoustic transducer such as a loudspeaker driver.
  • the apparatus optionally includes a drug delivery module 7 for delivering a drug such as ventilum to patient 1 directly or via the gas feed associated with pressure transducer 6.
  • Drug delivery module 7 receives its control signal from the digital processing unit of module 5. The signal to initiate drug delivery may be based on a consideration of a large number of patient variables available to module 5 via module 4.
  • Fig. 1A shows typical sound pressure waveforms associated with a snoring patient.
  • the sound pressure waveforms impinge upon microphone 2.
  • Successive bursts of waveforms are shown separated by a time "t". Where the time "t" is greater than about 10 seconds this may be interpreted by module 5 of the apparatus as an apnea episode.
  • Fig. 1 B shows the analog electrical signal at the output of microphone 2 which is inputted to amplifying and processing module 3 in Fig. 1.
  • Fig. 1C shows the (analog) gas control signal outputted by module 5 and inputted to module 6 in Fig. 1.
  • Fig. 1 D shows the actual airflow/ pressure associated with the gas (air) delivered via a conduit from module 6 to patient 1.
  • Fig. 1 E shows the sound pressure waveform of Fig. 1A in which the (horizontal) time axis has been expanded by a factor of 10.
  • Fig. 1F shows the actual airflow/pressure of Fig. 1D in which the (horizontal) time axis has been expanded by a factor of 10.
  • a comparison of the waveforms Figs. 1 E and 1 F shows that at time t, a peak in the waveform of Fig. 1 E is accompanied by a trough in the waveform of Fig. 1F, illustrating the phase reversal which gives rise to acoustical cancellation and compensates the effects of a prevailing breathing disorder.
  • a combination of the following processes can be operated in real-time either individually or concurrently at any time.
  • Block 1 represents the start of the system processes. Start can be initiated by selecting start recording from system control. Alternatively start process can be initiated by configuring the system to start at a predefined time or the device can be started automatically on power up of the apparatus.
  • Block 2 represents the system's event detection and recording function mode.
  • the apparatus may be used with minimal memory requirements, in which case the processing capabilities of the system to detect and record the occurrence and frequency of events such as snoring, allows a basic detection device.
  • the apparatus may be used to monitor patient's breathing sounds and record the events for purpose of a snore index which may allow a physician to determine the extent to which a patient is snoring.
  • the apparatus may detect the frequency and severity (by way of amplitude or sound level measurement) of snoring by a patient. This is the simplest operation mode of the apparatus as memory requirements are minimal.
  • the original sound does not need to be recorded and the apparatus is set up to detect snore events only and count them per unit time such as each hour, for example.
  • the patient can be recommended for further more advanced diagnosis and/or treatment if required.
  • the apparatus can be operated in a mode to store raw data from the input microphone and/or other input sensor(s).
  • This mode of operation can be operated in conjunction with the simpler above mentioned detection mode to allow the medical practitioner to detect a patient's breathing disorders such as snoring, while at the same time, provide a means of allowing the practitioner to review the patient raw data and validate the detection accuracy of the apparatus.
  • the former method of detection without the raw data recording function has the advantage of providing a lower cost device in that the memory requirements are less where the device only has to record the occurrence of an event and the time of this occurrence, as opposed to the recording of all the original raw data from the input signal(s).
  • RACFSS represents a mode of operation which allows the monitoring of a patients breathing sounds such as snoring, while at the same time generating a control signal to provide a modulated gas delivery to a subject.
  • the phase and airflow of the modulated gas delivery to the patient is related to the monitored sound signal from the patient. This is because snoring, due to vibration of the patient's upper palette, can be cancelled out or nulled out by way of an acoustic or pressure waveform of opposite polarity to the original sound source. In the example of snoring, vibration of the upper palette is counteracted by a pressure modulating the patient's palette in opposite polarity to the sound pressure waveforms originating the patient's snoring.
  • This "opposite polarity" pressure or acoustic cancellation can be applied to the patient by way of a nasal mask or full nasal and oral mask.
  • the delivery of the modulated gas to the patient is preferably such that the patient's breathing is stablilised with a minimum amount of gas.
  • the signal monitored from the patient can be sound, airflow, respiratory effort or other means of detecting the patient breathing.
  • This control of gas delivery is able to "track" the sound monitored from a patient in such a manner that sound pressure waves produced from the physiological effects of snoring (for example) can be cancelled out by applying a base pressure with a modulated pressure signal of opposite acoustic phase to the originating patient's snore sound.
  • the apparatus of the present invention is able to apply a modulated pressure waveform with a fast dynamic range and frequency together with a base line pressure, in order to provide acoustic cancellation of patient physiological sounds such as snoring.
  • This type of gas delivery device requires application of unique pressure drivers such as a diaphragm in order to apply the modulation at a frequency high enough to acoustically cancel out a patients snoring with minimal modulated air pressure/flow and minimal base level pressure.
  • Block 3 can operate individually or in combination with the processes of block 2 or block 4.
  • Block 3 is operated as an individual process the system is used in a mode of therapeutic control whereupon a subject can be treated for disorders such as apnea, snoring, hypopnea, amongst others.
  • Block 4 represents the systems capability to provide a means to review: a) monitored raw dafajnput from the microphone; b) review events detected by the apparatus in order to validate the precision and accuracy of event detection capabilities of the apparatus. This function is helpful to provide to a user of the apparatus a level of validation supporting any diagnostic decision that evolves from the use of the apparatus; c) Selective or random sample event storage. This mode of operation allows the apparatus to store one or more selective or random samples of detected events. While only a limited set of raw data samples are stored, all events may be detected, counted and summarised in terms of events per unit time eg. per hour. This technique may reduce storage requirements significantly while still providing a means for validating a recorded event by recording one or more typical detected events.
  • FIG. 3A and 3B A flow diagram associated with operation of Block 2 (sound and respiratory event detector/recorder) in Fig. 2 is shown in Figs. 3, 3A and 3B. With reference to Figs. 3, 3A and 3B the following is a description of the steps associated with Block 2.
  • Step 1 represents the system start which could be operated by selecting power on, the pre-programming of a particular start-time, by applying power to the apparatus or alternatively by remote start command.
  • Step 2 represents converting of data from the input source to a digital format so that this can be further processed in digital mode by the central processing unit of the apparatus.
  • This input data can be, but is not limited to the input from a microphone.
  • the input data can be from other means of detecting patient breathing which could be for example from; an airflow sensor such as a thermistor breathing sensor, thermo-coupler breathing sensor, respiratory effort sensors, sounds recorded from a patient breathing mask (nasal or nasal and oral), a vibration sensor device attached to the patient or -other means of monitoring the patient's breathing sounds or physiology.
  • STEP 3 is converting of data from the input source to a digital format so that this can be further processed in digital mode by the central processing unit of the apparatus.
  • This input data can be, but is not limited to the input from a microphone.
  • the input data can be from other means of detecting patient breathing which could be for example from; an airflow sensor such as a thermistor breathing sensor, thermo-coupler breathing sensor, respiratory effort sensors,
  • Step 3 represents primary processing capabilities of the apparatus including the following:
  • RACFSS a necessary function when determining whether the application of RACFSS is having the desired affect in relation to stabilising the patient's breathing, ie. is the application of increased and/or modulated air pressure or airflow by way of nasal breathing mask removing the symptoms of snoring, or is the application of ventilum by way of face mask removing the symptoms of asthma (ie is wheezing subsiding). Both these examples are direct applications of RACFSS.
  • SA provides a breakdown of the frequency spectrum in terms of amplitude and frequency bands. This type of analysis can also incorporate amplitude or half- period-amplitude analysis.
  • the sample period for spectral analysis can be varied within the processing stages to determine both recognition of instantaneous breathing sound changes and longer term breathing sound changes.
  • the parameters by which the SA processing variables are configured are determined by the user of the apparatus or preset from clinical studies.
  • FFT Fast Fourier transform
  • the sample period for the FFT can be varied within the processing stages to determine both recognition of instantaneous breathing sound changes and longer term breathing sound changes.
  • the parameters by which the FFT processing variables are configured are determined by the user or the apparatus or preset from clinical studies.
  • Amplitude of the input microphone signal can be determined for the following conditions; each period amplitude each Vi period amplitude average amplitude over various time intervals (ie . 14 second, 1 second, 5 seconds, 10 seconds, 20 seconds, 30 seconds, 1 minute, 5 minutes). running average amplitude- ie average level recalculated after each new 14 period or period of monitored signal where the interval for average amplitude can be 14 second, 1 second, 5 seconds, 10 seconds, 20 seconds, 30 seconds, 1 minute, 5 minutes or other durations.
  • the period over which the signal average is determined can be configured by the user of the apparatus or preset from clinical studies.
  • Signal to Noise analysis can determine normal system noise by shorting out input stage electronics and removing external sound, in order to calibrate the system for external noise against system electronic noise. Advanced signal to noise analysis can also distinguish, in part, patient breathing sounds against unwanted room noise. The determination of background noise can allow accurate threshold calculation in order to precisely set a point at which microphone signal should be ignored.
  • Step 4 represents an optional capability of the apparatus to store monitored patient data together with primary analysis data onto permanent or semipermanent devices such as hard disk or removable flash disk devices. This function is indicated as optional because the apparatus can be configured with no or minimal permanent or semi-permanent storage capabilities in order to reduce the manufacturing cost of the apparatus.
  • This type of storage is necessary to ensure that raw data from the monitored patient input can be reviewed either remotely or locally during the systems operation or at a later time.
  • the reviewing of the data can be required by the physician or user of the apparatus.
  • a review of this raw data allows a validation of the type of information monitored by the apparatus and also allows the apparatus to indicate to the user where and what events were detected.
  • the user of the apparatus can validate the detection algorithms and processing capability of the apparatus, which is an important factor in the use of the apparatus for providing reliable patient diagnosis.
  • the number of false event detections may increase and render operation of the apparatus unacceptable. This may be determined by viewing the recorded data and noting whether any events were undetected or falsely detected by utilising an experienced person's capability in scrutinising system performance.
  • Step 5 represents the system's RAM which can be used to store various processing requirements of the apparatus, together with minimal data storage requirements such as the detection of events, the frequency of detection of events (ie events per hour), random or selective storage of events, patient identification, amongst other storage requirements.
  • Step 6 represents secondary processing capabilities of the apparatus. This includes an ability to review the output of the primary analysis determined in step 3 above and stored in step 4 and/or 5.
  • the various primary output data needs to be correlated with each type of secondary analysis in order to provide a more accurate means of identifying valid secondary physiological events. For example the recognition of longer term physiological breathing patterns as distinct from shorter term and irregular environmental noise provides a basis of more accurate detection than detections involving less processing and having less discriminatory detection capabilities.
  • Physiological breathing sounds refers to sound recorded from the patient as opposed to back ground electronic system noise and background room noise.
  • Signal to Noise analysis (step 3) deals with calibration of system noise while the calibration of room noise against physiological noise is more complex due to the cast variety of possible room noise.
  • Physiological breathing sounds refers to normal breathing sounds and various disordered breathing sounds such as snoring, wheezing, caughing, amongst others.
  • Physiological breathing sounds may be, determined by comparing actual data (refer outputs marked A, B, C, D, F in Fig. 3) to prestored data that characterise various breathing and sleep disorders. The prestored data can be determined by comprehensive clinical trials.
  • Breathe by breathe frequency analysis can be analysis classification of each breathing cycle in terms of amplitude, spectral and/or fast fourier transform data. These frequency and amplitude characteristics as determined for each breathing cycle (where each breathing cycle is detected in step 6 above) are then collated in terms of frequency and amplitude characterisation for each and every breathing cycle.
  • By characterising each breathing cycle in this manner it is possible to provide a level of background noise discrimination (environmental and electronic system noise). This noise discrimination is possible as breathing noises can be related to the peak and trough points of the breathing cycle, for example. Background noise will not be associated with the breathing cycle as will physiological breathing noises. This is an example of how noise discrimination can be implemented within step 6.
  • Environmental sound Environmental noise is the total sound recorded minus the electronic signal noise and the physiological breathing sounds.
  • a "patient's sleep state" can be determined by the apparatus by simple means such as arousal detection. These arousal detections can be by way of monitoring additional channels such as movements from a special sensitive mattress.
  • the mattress may be a piezo ceramic or capacitive discharge type. In both these aforementioned mattress types the apparatus is able to monitor the frequency, amplitude and regularity of patient body movements as an indicator as to whether or not the patient is likely to be asleep.
  • Step 7 represents tertiary processing capabilities of the apparatus. This includes a final analysis by referencing the information from step 6 (which determines valid physiological events as opposed to background and system noise- secondary analysis) and categorises the physiological event data into categories as recognised by medical physicians in the determination of a patients respiratory disorder or sleep disorder diagnosis.
  • This categorisation can include recognition of an apnea event.
  • the latter is typically recognised by a lapse in breathing during a "patient's sleep state" for a period greater than 10 seconds. In the context of the present invention this could be recognised by detection of snoring sounds punctuated by relative breathing silence for 10 seconds or greater.
  • This type of analysis and categorisation can provide a means of presenting a snoring index or number of snores per hour. The number of snores per hour is recognised by the medical user of the apparatus as an indicator that the patient is suffering from Obstructive Sleep Apnea for example.
  • This technique of comparing a currently monitored patient signal characteristics with the signal characteristics from a range of typical parameters from a sample of respiratory disorders assists the apparatus of the present invention to provide quick and accurate detection of a number of respiratory disorders with minimal channels required for monitoring (ie in the most common implementation of RACFSS, a simple microphone channel).
  • Step 7 also has the function of comparing each patient's breathing cycle with a data base of patient breathing characteristics.
  • This data-base of breathing characteristics which may be derived from prior clinical studies, allows matching of frequency and amplitude characteristics of various breathing disorders. In this way a comparison of the current patient's frequency and amplitude characteristics with a known data base of characteristics and associated disorders may assist in accurate diagnosis of the patient's breathing disorders. For example, if the patient is wheezing, the frequency and amplitude characteristics of this sound analysis is likely to match with the reference data base for a diagnostic classification of wheezing, which together with other patient states may lead to the diagnosis of asthma. This diagnosis may lead to the delivery of ventilum. The output state or event in this case could be high level wheezing.
  • wheezing RACFSS could be replaced with a ventilum delivery device as the feedback element.
  • the application of ventilum to the patient as the feedback element to cancel out the acoustic symptom of wheezing manifests itself as a precise and accurate method of delivering the absolute minimum but highly responsive treatment of wheezing-related asthma.
  • ventilum track algorithm could, for example (in a therapeutic mode of the apparatus) increase or decrease ventilum delivery to the patient until the wheezing state ceases.
  • the optimum value of ventilum delivery could then be stored into a diagnostic ventilum set look-up-table (for later diagnostic reference by the supervising medical practitioner).
  • Various values for ventilum delivery could therefore be determined in this way having regard to each patient state or breathing event.
  • Step 8 represents a capability of apparatus to store the monitored event type (ie snoring, wheezing, apnea), event time, event duration into hard disk, flash disk or other permanent or semi-permanent storage type.
  • the monitored event type ie snoring, wheezing, apnea
  • event time ie snoring, wheezing, apnea
  • event duration into hard disk, flash disk or other permanent or semi-permanent storage type.
  • This function may be optional because as noted above the apparatus can be configured with no or minimal permanent or semi-permanent storage capabilities in order to reduce the manufacturing cost of the apparatus.
  • a review of this raw data allows a validation of the type of information monitored by the apparatus and also allows the apparatus to indicate to the user where and what events were detected.
  • the user of the system can validate the detection algorithms and processing capability of the apparatus, which is an important factor in the use of the apparatus for providing reliable patient diagnosis.
  • Step 9 represents the system's RAM or other permanent storage facility which can be used to store various processing requirements of the apparatus, together with minimal data storage requirements such temporary storage of tertiary analysis results.
  • Temporary storage can be suitable for the purpose of providing to the user of the apparatus, a means of having a summary of the patient diagnosis.
  • This diagnosis in the simplest form could be, for example, a snoring index (eg. snores per hour).
  • Step 10 provides "Stop Record” mode. This is achieved by detecting whether the system has a valid pre-programmed stop time, whether the system has been selected for off or whether the system power has been switched off.
  • Step 11 ends the process and follows step 10 system off selection.
  • FIG. 4 and 4A A flow diagram associated with operation of Block 3 (respiratory acoustic cancellation feedback servo system - RACFSS) in Fig. 2 is shown in Figs. 4 and 4A. With reference to Figs. 4 and 4A, the following is a description of the steps associated with Block 3.
  • Step 1 represents the system start which could be operated by selecting power on, the pre-prog ramming of a particular start-time, by applying power to the apparatus or alternatively by remote start command.
  • STEP 2 represents the system start which could be operated by selecting power on, the pre-prog ramming of a particular start-time, by applying power to the apparatus or alternatively by remote start command.
  • Step 1 represents the function of the device which detects the system user's selection of therapeutic mode.
  • the selection of therapeutic mode is optional and allows the system to provide control for a gas delivery device, while at the same time providing detection and monitoring of respiratory disorders.
  • the therapeutic function may not be required where the apparatus is to be used as an indicator of snoring or apnea but would be required where the apparatus is to be used for the purpose of monitoring sound while at the same time providing gas delivery control utilising the acoustic cancellation capabilities of the apparatus.
  • Step 3 analyses input data including microphone input data.
  • the input data is analysed by reviewing the primary, secondary and tertiary results as detailed in the flow diagram of figure 3.
  • Step 4 decides whether a respiratory event or the start of a respiratory event is detected.
  • the apparatus will prepare itself to track the signal amplitude detected from a respiratory event in order to be able to produce a control signal for the purpose of physiological event cancellation by way of gas delivery.
  • Step 5 produces the control signal for the purpose of providing an appropriate base level pressure and modulated pressure.
  • This control signal contains both a base level or low frequency pressure or airflow control and a higher frequency modulated pressure or airflow control.
  • the apparatus produces the control signal for controlling an external device.
  • the apparatus could be integrated into a gas delivery device which provides the capability to regulate the pressure or airflow to a patients face mask (ie nasal or full mask).
  • This pressure control can be similar in frequency and opposite in phase to the original acoustic waves as detected by the microphone.
  • the apparatus should have sufficient processing capability to produce this opposite phase air flow modulation together with a base pressure in order to cancel out physiological events such as snoring with a minimum pressure applied to the patient (ie by way of nasal mask). It is desirable to keep the delivery of pressure to the patient at a minimum in order to minimise the discomfort to the patient and also to minimise side effects from therapeutic intervention by way of gas delivery.
  • the apparatus of the present invention is unique in its ability to produce a servo loop effect in the application of patient gas delivery.
  • the apparatus may apply a precise amount of opposite phase modulated pressure to stabilise the vibrating upper palette.
  • the apparatus can provide the combination of base pressure and modulated pressure waveforms by utilising conventional technology to produce a continuous or slowly varying (low frequency) gas delivery - such as a range of pressure (say 0 CMH20 to 20 CMH20 range) with variation of rate of pressure or airflow change from say continuous to 10 cycles per second.
  • the apparatus may provide a higher frequency modulated gas delivery - such as a range of pressure (say 0 CMH20 to 3 CMH20 range) with variation of rate of pressure or airflow change from say .5 cycles per second to say 1000 cycles per second.
  • the apparatus of the present invention may provide these two forms of gas delivery, being continuous and higher frequency gas modulation.
  • the latter may be provided by means of a diaphragm (similar to the cone of the driver of an audio loudspeaker) to modulate the low frequency or continuous gas delivery obtainable from a conventional respiratory ventilator or air delivery blower device.
  • a diaphragm similar to the cone of the driver of an audio loudspeaker
  • High frequency pressure rate changes and low frequency base pressure changes may be continuously checked by the system control so as not to exceed preprogrammed patient safety limits. These pressure limits may be detected and checked by way of two methods;
  • System control may limit the amount of base pressure and modulation control output from the system in order to not exceed preset patient limits.
  • the apparatus may monitor gas delivery to the patient by way of a pressure or airflow sensor interfaced to the patients breathing. This interface can be by way of a sensor attached to the patient's breathing mask, for example.
  • the monitored airflow or pressure may be limited by the apparatus to fall within safe patient limits as reprogrammed by the system or the system user (supervising medical practitioner).
  • Step 7 functions to correct any excessive pressure or airflow modulation to remain within safe patient limits.
  • Step 8 compares microphone signal's current data with the microphone signal's previous data and determines through processes of comparing alignment and subtraction, whether activated pressure changes are having an effect on the amplitude of the respiratory event. That is, is the effect of pressure activation change causing the current respiratory event (ie snoring sound) to reduce in presence as measured by a decrease in the amplitude of the sound signal.
  • the current respiratory event ie snoring sound
  • Step 9 determines whether pressure or airflow change activation reduce the effect of the respiratory event, ie does snoring subside.
  • the purpose of this step is to determine whether or not the application of a change of pressure and airflow to the patient is directly related to reducing the symptoms of the patient's respiratory disorder.
  • Step 11 ends the process and follows step 10 system off selection.
  • Fig. 5 shows one example whereby a continuous gas delivery system can be modified in accordance with the principles of the present invention. Modification is by means of a T section element 50 inserted into the supply of base or continuous pressure or airflow 51 associated with the system.
  • the modification comprises an air pressure modulator 52 (refer module 6 in Fig. 1) placed in communication with the leg of T section element 50 such that air pressure changes produced by modulator 52 are impressed upon the base or continuous pressure or airflow 51 to form a composite pressure/air flow 53.
  • Composite flow 53 comprises a combination of base pressure 51 and modulated pressure/airflow produced via modulator 52.
  • the air pressure changes impressed via modulator 52 are generally of a substantially higher frequency than changes that may be produced by the continuous gas delivery system.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Apparatus for controlling gas or drug delivery to a patient, said delivery being adapted to maintain effective respiratory function. The apparatus includes means (2, 3, 4) for monitoring one or more physiological variables such as breathing airflow sound, EEG, EOG, EMG and/or patient position associated with the patient. The apparatus also includes means (4) for deriving from the variables, data representing a physiological state associated with the patient and means (5) for determining from the data, a gas pressure or drug quantity which substantially prevents a deterioration in the state. The determining means may include an algorithm adapted to generate a gas pressure signal which is substantially 180° out of phase relative to the phase of the patient breathing and/or sound. The apparatus may include a gas delivery means (6) for delivering gas to the patient in accordance with the determined gas pressure. The apparatus may include a drug delivery module (7) for delivering a drug to the patient.

Description

CONTROLLING GAS OR DRUG DELIVERY TO PATIENT
The present invention relates to apparatus for controlling gas delivery to a patient. The apparatus of the present invention is related to apparatus disclosed in applicant's copending PCT application AU96/00679 filed 31 October 1996 and in AU Patent 632932 entitled "Analysis System for physiological variables", the disclosures of which are incorporated herein by cross reference.
The apparatus of the present invention may provide a diagnostic and/or a therapeutic function. The diagnostic function may include monitoring and/or diagnosis of physiological variables associated with the patient. The therapeutic function may include application of controlled gas delivery to the patient. The diagnostic and therapeutic functions may be performed in a single device having integrated functions or it may be performed via two or more separate devices.
The apparatus of the present invention is particularly useful for investigation, diagnosis and treatment of sleep, respiratory and sleep related respiratory disorders, sleep propensity, fatigue and asthma and will be described herein in that context. Nevertheless it is to be appreciated that it is not thereby limited to such applications.
The apparatus of the present invention has been developed for, but is not limited to monitoring, analysing, storing, controlling and networking physiological variables. The aforementioned "controlling of physiological variables" includes controlling the gas delivery to a patient. This gas can be but is not limited to air as used in a CPAP (Continuous Positive Air Pressure) application, or one of the many variations of positive air pressure delivery to a patient known in the art.
Due to the complex and varying states of sleep and the broad range of sleep disorders that can be diagnosed, many different physiological variables and events can be simultaneously monitored, analysed and stored by the present apparatus. The monitored physiological variables and events can include one or more channels of each of the following signal types:
Breathing and snoring sounds CPAP mask sound ( monitoring for patients breathing sounds within CPAP mask).
These sounds include snoring, wheezing and other disordered breathing sounds • Brain waves/Electroencephalogram (EEG)
• Eye Movement/Electro-oculogram (EOG)
• Muscle function/Electro-myogram (submental EMG from muscles under the chin)
Muscle function/Electro-myogram (diaphragm EMG from respiratory effort)
Muscle function/Electro-myogram (other EMG reflecting muscle and nerve activity either by invasive or non-invasive monitoring)
• Status of patient position
• Leg movements (Left and/or Right legs)
• Heart beat/Electrocardiogram (ECG)
• Oximetry (Sa 02 - Oxygen saturation)
• Carbon dioxide monitoring CO2
• Respiratory effort (Abdominal, thoracic or otherwise)
• Airflow (Nasal or oral)
• Continuous Positive Airflow Pressure (monitoring of patients mask pressure during application of CPAP treatment)
CPAP mask temperature (monitoring of CPAP mask air temperature for breathing activity and airflow of patient) • Status of lights
• Graphic processing of video image (allows determination of whether patients eyes are open or closed).
• Patient digital video recording and graphic processing techniques for determination of eye lid activity (ie status of patient eyes being opened or closed - relative to fully closed or fully opened eyes status).
• Time and date stamping of monitored physiological data, video and sound.
• Infrared Video monitoring (for night studies)
• Complex sound analysis (accurate full bandwidth or limited bandwidth recording and analysis of breathing sounds. The sound is analysed and compared with criteria or a data base, consisting of reference data for disordered breathing. Microphones may be servo controlled for automatic axis adjustment to allow optimum focus on breathing sounds.)
• Physiological events: ie ECG arrhythmia, EEG spike detection, EEG spindles amongst others
• Local area networked monitoring, analysis and/or storage of a patient's physiological variables
• Endoscopy
• Breath by breath analysis-pnuemotachograph • 3 D imaging
• Virtual patient monitoring
• Infrared eye detection for fatigue and sleep monitoring
• EEG delta and alpha-wave detection
• Eye position and movements by way of Infrared Eye Detection • Delta Wave detections and related sleep/fatigue/impairment detection
• Mattress Device: monitoring of patient sleep state and respiratory parameters by using a mattress sensor device. The matress device can be used to monitor a patient's electro-oculogram, sleep state, arousals, position, electrocardiogram. There are presently two types commercially available mattress devices; Static Charge-sensitive Bed (SCSB) and polyvinylidene fluoride (PVDF - piezoelectric plastic). When monitoring sleep states, sleep propensity, respiratory disorders, vigilance state or fatigue of a subject, one or more physiological variables as listed above may be continuously monitored and/or analysed and/or stored.
The present invention allows one or more channels of patient variables and/or events to be monitored, processed and recorded, while at the same time allowing precise data interconnection with a remote site. This remote site can view, process or record the real-time patient data. The communication link can take the form of a range of transmission media, including but not limited to wireless interconnection such as spread spectrum transmission wireless LAN.
The prior art provides devices for the purpose of regulating a patients breathing but these devices are unable to apply principles of acoustic cancellation as proposed by the present invention. While the applicant appreciates that prior systems can monitor patient breathing sound and in particular snoring, these earlier devices were not developed to modulate gas delivery to a patient in a way which can acoustically cancell vibration in the patient's upper palette.
According to the present invention there is provided apparatus for controlling gas delivery to a patient, said delivery being adapted to maintain effective respiratory function, said apparatus including: means for monitoring one or more physiological variables associated with said patient; means for deriving from said one or more variables, data representing a respiratory state associated with said patient; and means for determining from said data, a gas pressure value which substantially prevents a deterioration in said state.
The monitoring means may include means such as a plurality of sensors and/or transducers for acquiring and monitoring variables representing physiological states associated with the patient. The physiological variables can include respiratory effort, breathing airflow, oximetry and/or sound. To this end the monitoring means includes an air pressure wave or sound/acoustic vibration transducer to monitor breathing sound and/or air pressure waves associated with the patient's respiratory function. The air or sound pressure wave transducer may include a sound microphone, air pressure sensor, air flow sensor or similar device. The air/sound pressure wave transducer may be located near the patient such as being incorporated in the nasal or nasal and oral mask used to deliver gas to the patient, or at any other location suitable for monitoring patient airflow and/or sound. Alternatively or additionally the apparatus may include other respiratory parameters input for the purpose of monitoring and detection of respiratory effort and/or respiratory disorders.
The or each sensor and/or transducer may generate an analog signal representative of variables being monitored. The monitoring means may include means for amplifying and/or performing analog processing on the analog signal. The latter may perform filtering and/or other wave shaping functions. The processed signal may be fed to an analog to digital converter to convert the or each analog signal to a corresponding digital signal. The or each digital signal may be fed to a digital processor such a microprocessor or microcomputer. The digital processor may include software for deriving from the or each digital signal data representing the patients respiratory state. The software may include means such as an algorithm for determining from the data a gas pressure value which substantially prevents a deterioration of the respiratory state. The algorithm may be adapted to generate a gas pressure signal which is substantially 180° out of phase relative to the phase of the patient breathing air flow and/or sound together with an option of a further gas pressure signal which changes relatively slowly when compared to the out of phase signal. The latter may be used to control delivery of gas to the patient to cancel out or substantially compensate the effects of a breathing disorder. In the event that the breathing disorder is not substantially corrected the software may be adapted to activate delivery of a drug such as ventilum. This may circumvent what may otherwise be a fatal or severe asthma attack. The software may additionally be adapted to determine quantity requirements of the drug. The latter may be based on the patients history and the extent to which the disorder fails to respond to gas pressure treatment.
A preferred embodiment of the present invention will now be described with reference to the accompanying drawings wherein:-
Figure 1 shows a block diagram of one form of gas delivery apparatus according to the present invention;
Figs. 1 A to 1 F show waveforms associated with the apparatus of Fig. 1 ;
Fig. 2 shows an overview of system software which may be used in conjunction with the apparatus shown in Fig. 1 ;
Figs. 3, 3A and 3B show a flow diagram of the sound and respiratory event detector /recorder;
Figs. 4 and 4A show a flow diagram of the respiratory acoustic cancellation feedback servo system; and
Fig. 5 shows one form of gas delivery system modified in accordance with the principles of the present invention.
Referring to Fig. 1 of the drawings, microphone 2 picks up sound from patient 1 and converts this to an electrical signal. The electrical signal from microphone 2 is analog in nature and is passed to signal amplifying and processing module 3.
Amplifying and processing module 3 amplifies the analog signal and performs filtering and/or wave shaping as required. The analog signal then passes to module 5. Module 5 also receives data from one or more sensors and/or transducers adapted to monitor a range of physiological variables associated with patient 1 such as respiratory effort, respiratory airflow, patient oxygen saturation, brain waves (EEG), heart beat (ECG), eye movement (EOG) muscle function (EMG), patient position and the like. The latter are represented by module 4 which provides analog signals representing the monitored physiological variables to module 5.
Module 5 includes one or more analog to digital convertors and a digital central processing unit (CPU) such as a microprocessor or microcontroller. The CPU is loaded with software including one or more processing algorithms for generating, inter alia, a gas control signal. The gas control signal may be adapted to produce a constant or varying gas pressure and/or air flow as required to compensate a prevailing respiratory disorder.
The gas control signal is fed to pressure transducer 6 to produce a gas pressure which is of a similar frequency but is substantially 180° out of phase relative to the phase of the respiratory signal picked up by microphone 2. The antiphase gas pressure produced by pressure transducer 6 is fed to the patient 1 via a conduit such as a plastics tube and may be applied via the nasal or nasal and oral mask to substantially cancell or compensate the effect of the prevailing breathing disorder. Pressure transducer 6 may include a pressure valve for controlling gas pressure or an acoustic transducer such as a loudspeaker driver.
The apparatus optionally includes a drug delivery module 7 for delivering a drug such as ventilum to patient 1 directly or via the gas feed associated with pressure transducer 6. Drug delivery module 7 receives its control signal from the digital processing unit of module 5. The signal to initiate drug delivery may be based on a consideration of a large number of patient variables available to module 5 via module 4.
Referring to Figs. 1A to 1 F, Fig. 1A shows typical sound pressure waveforms associated with a snoring patient. The sound pressure waveforms impinge upon microphone 2. Successive bursts of waveforms are shown separated by a time "t". Where the time "t" is greater than about 10 seconds this may be interpreted by module 5 of the apparatus as an apnea episode.
Fig. 1 B shows the analog electrical signal at the output of microphone 2 which is inputted to amplifying and processing module 3 in Fig. 1.
Fig. 1C shows the (analog) gas control signal outputted by module 5 and inputted to module 6 in Fig. 1.
Fig. 1 D shows the actual airflow/ pressure associated with the gas (air) delivered via a conduit from module 6 to patient 1.
Fig. 1 E shows the sound pressure waveform of Fig. 1A in which the (horizontal) time axis has been expanded by a factor of 10.
Fig. 1F shows the actual airflow/pressure of Fig. 1D in which the (horizontal) time axis has been expanded by a factor of 10.
A comparison of the waveforms Figs. 1 E and 1 F shows that at time t, a peak in the waveform of Fig. 1 E is accompanied by a trough in the waveform of Fig. 1F, illustrating the phase reversal which gives rise to acoustical cancellation and compensates the effects of a prevailing breathing disorder.
Referring to Fig. 2 of the drawings, a combination of the following processes can be operated in real-time either individually or concurrently at any time.
(a) Sound and respiratory event detector/recorder.
(b) Sound and respiratory event detector/recorder replay system.
(c) Acoustic feedback servo system.
The following is a description of each mode of operation with reference to a typical application, being snore detection. BLOCK 1
Block 1 represents the start of the system processes. Start can be initiated by selecting start recording from system control. Alternatively start process can be initiated by configuring the system to start at a predefined time or the device can be started automatically on power up of the apparatus.
BLOCK 2
Sound and respiratory event detector/recorder
Block 2 represents the system's event detection and recording function mode. The apparatus may be used with minimal memory requirements, in which case the processing capabilities of the system to detect and record the occurrence and frequency of events such as snoring, allows a basic detection device.
For example, the apparatus may be used to monitor patient's breathing sounds and record the events for purpose of a snore index which may allow a physician to determine the extent to which a patient is snoring. The apparatus may detect the frequency and severity (by way of amplitude or sound level measurement) of snoring by a patient. This is the simplest operation mode of the apparatus as memory requirements are minimal. The original sound does not need to be recorded and the apparatus is set up to detect snore events only and count them per unit time such as each hour, for example. By providing to a medical practitioner an indication of how many snores per hour are detected, and the sound level of these snores, the patient can be recommended for further more advanced diagnosis and/or treatment if required.
Alternatively the apparatus can be operated in a mode to store raw data from the input microphone and/or other input sensor(s). This mode of operation can be operated in conjunction with the simpler above mentioned detection mode to allow the medical practitioner to detect a patient's breathing disorders such as snoring, while at the same time, provide a means of allowing the practitioner to review the patient raw data and validate the detection accuracy of the apparatus.
The former method of detection without the raw data recording function has the advantage of providing a lower cost device in that the memory requirements are less where the device only has to record the occurrence of an event and the time of this occurrence, as opposed to the recording of all the original raw data from the input signal(s).
BLOCK 3
Respiratory Acoustic Cancellation Feedback Servo System (RACFSS)
RACFSS represents a mode of operation which allows the monitoring of a patients breathing sounds such as snoring, while at the same time generating a control signal to provide a modulated gas delivery to a subject. The phase and airflow of the modulated gas delivery to the patient is related to the monitored sound signal from the patient. This is because snoring, due to vibration of the patient's upper palette, can be cancelled out or nulled out by way of an acoustic or pressure waveform of opposite polarity to the original sound source. In the example of snoring, vibration of the upper palette is counteracted by a pressure modulating the patient's palette in opposite polarity to the sound pressure waveforms originating the patient's snoring. This "opposite polarity" pressure or acoustic cancellation can be applied to the patient by way of a nasal mask or full nasal and oral mask. The delivery of the modulated gas to the patient is preferably such that the patient's breathing is stablilised with a minimum amount of gas.
The signal monitored from the patient can be sound, airflow, respiratory effort or other means of detecting the patient breathing.
This control of gas delivery is able to "track" the sound monitored from a patient in such a manner that sound pressure waves produced from the physiological effects of snoring (for example) can be cancelled out by applying a base pressure with a modulated pressure signal of opposite acoustic phase to the originating patient's snore sound.
While the prior art includes Continuous Positive Air Pressure (CPAP) devices (Sullivan), Variable Positive Air Pressure devices (VPAP), Demand Positive Pressure devices, Autoset (designed by ResMed to automatically adjust CPAP pressure), the apparatus of the present invention is able to apply a modulated pressure waveform with a fast dynamic range and frequency together with a base line pressure, in order to provide acoustic cancellation of patient physiological sounds such as snoring. This type of gas delivery device requires application of unique pressure drivers such as a diaphragm in order to apply the modulation at a frequency high enough to acoustically cancel out a patients snoring with minimal modulated air pressure/flow and minimal base level pressure.
The process of Block 3 can operate individually or in combination with the processes of block 2 or block 4. When Block 3 is operated as an individual process the system is used in a mode of therapeutic control whereupon a subject can be treated for disorders such as apnea, snoring, hypopnea, amongst others.
BLOCK 4
Sound and respiratory event detector/recorder replay system
Block 4 represents the systems capability to provide a means to review: a) monitored raw dafajnput from the microphone; b) review events detected by the apparatus in order to validate the precision and accuracy of event detection capabilities of the apparatus. This function is helpful to provide to a user of the apparatus a level of validation supporting any diagnostic decision that evolves from the use of the apparatus; c) Selective or random sample event storage. This mode of operation allows the apparatus to store one or more selective or random samples of detected events. While only a limited set of raw data samples are stored, all events may be detected, counted and summarised in terms of events per unit time eg. per hour. This technique may reduce storage requirements significantly while still providing a means for validating a recorded event by recording one or more typical detected events. An example where this function would be useful is where a patient is monitored for snoring but where false detections through excessive background noise could be indicated by allowing the user to review some sample recorded events, which may include excessive background noise, and indicate that the system results should be observed with caution.
A flow diagram associated with operation of Block 2 (sound and respiratory event detector/recorder) in Fig. 2 is shown in Figs. 3, 3A and 3B. With reference to Figs. 3, 3A and 3B the following is a description of the steps associated with Block 2.
STEP 1
Step 1 represents the system start which could be operated by selecting power on, the pre-programming of a particular start-time, by applying power to the apparatus or alternatively by remote start command.
STEP 2
Step 2 represents converting of data from the input source to a digital format so that this can be further processed in digital mode by the central processing unit of the apparatus. This input data can be, but is not limited to the input from a microphone. Alternatively or additionally the input data can be from other means of detecting patient breathing which could be for example from; an airflow sensor such as a thermistor breathing sensor, thermo-coupler breathing sensor, respiratory effort sensors, sounds recorded from a patient breathing mask (nasal or nasal and oral), a vibration sensor device attached to the patient or -other means of monitoring the patient's breathing sounds or physiology. STEP 3
Step 3 represents primary processing capabilities of the apparatus including the following:
Breathe by Breathe detection
Breathe by breathe analysis allows the "zero crossing" of each breathing cycle to be detected in order to separately classify each patient's breathing cycle. Classifying each breathing cycle allows secondary and tertiary analysis to compare a current patient breathing cycle with a previous breathing cycles in order to determine any change in characteristics of the patient breathing. This is a necessary function when determining whether the application of RACFSS is having the desired affect in relation to stabilising the patient's breathing, ie. is the application of increased and/or modulated air pressure or airflow by way of nasal breathing mask removing the symptoms of snoring, or is the application of ventilum by way of face mask removing the symptoms of asthma (ie is wheezing subsiding). Both these examples are direct applications of RACFSS.
Spectral Analysis (SA)
SA provides a breakdown of the frequency spectrum in terms of amplitude and frequency bands. This type of analysis can also incorporate amplitude or half- period-amplitude analysis. The sample period for spectral analysis can be varied within the processing stages to determine both recognition of instantaneous breathing sound changes and longer term breathing sound changes. The parameters by which the SA processing variables are configured are determined by the user of the apparatus or preset from clinical studies.
Fast Fourier transform (FFT) FFT is a conventional form of analysis and is provided for the purpose of determining the power monitored at various frequencies. The sample period for the FFT can be varied within the processing stages to determine both recognition of instantaneous breathing sound changes and longer term breathing sound changes. The parameters by which the FFT processing variables are configured are determined by the user or the apparatus or preset from clinical studies.
Amplitude Determination Analysis
Amplitude of the input microphone signal can be determined for the following conditions; each period amplitude each Vi period amplitude average amplitude over various time intervals (ie . 14 second, 1 second, 5 seconds, 10 seconds, 20 seconds, 30 seconds, 1 minute, 5 minutes). running average amplitude- ie average level recalculated after each new 14 period or period of monitored signal where the interval for average amplitude can be 14 second, 1 second, 5 seconds, 10 seconds, 20 seconds, 30 seconds, 1 minute, 5 minutes or other durations.
The period over which the signal average is determined can be configured by the user of the apparatus or preset from clinical studies.
Signal to Noise Analysis Signal to noise analysis can determine normal system noise by shorting out input stage electronics and removing external sound, in order to calibrate the system for external noise against system electronic noise. Advanced signal to noise analysis can also distinguish, in part, patient breathing sounds against unwanted room noise. The determination of background noise can allow accurate threshold calculation in order to precisely set a point at which microphone signal should be ignored.
STEP 4
Step 4 represents an optional capability of the apparatus to store monitored patient data together with primary analysis data onto permanent or semipermanent devices such as hard disk or removable flash disk devices. This function is indicated as optional because the apparatus can be configured with no or minimal permanent or semi-permanent storage capabilities in order to reduce the manufacturing cost of the apparatus.
This type of storage is necessary to ensure that raw data from the monitored patient input can be reviewed either remotely or locally during the systems operation or at a later time. The reviewing of the data can be required by the physician or user of the apparatus. A review of this raw data allows a validation of the type of information monitored by the apparatus and also allows the apparatus to indicate to the user where and what events were detected. Thus the user of the apparatus can validate the detection algorithms and processing capability of the apparatus, which is an important factor in the use of the apparatus for providing reliable patient diagnosis.
If, for example, the apparatus is used in noisy environments the number of false event detections may increase and render operation of the apparatus unacceptable. This may be determined by viewing the recorded data and noting whether any events were undetected or falsely detected by utilising an experienced person's capability in scrutinising system performance.
STEP 5
Step 5 represents the system's RAM which can be used to store various processing requirements of the apparatus, together with minimal data storage requirements such as the detection of events, the frequency of detection of events (ie events per hour), random or selective storage of events, patient identification, amongst other storage requirements.
STEP 6
Step 6 represents secondary processing capabilities of the apparatus. This includes an ability to review the output of the primary analysis determined in step 3 above and stored in step 4 and/or 5. The various primary output data needs to be correlated with each type of secondary analysis in order to provide a more accurate means of identifying valid secondary physiological events. For example the recognition of longer term physiological breathing patterns as distinct from shorter term and irregular environmental noise provides a basis of more accurate detection than detections involving less processing and having less discriminatory detection capabilities.
Valid Physiological Breathing Sounds Valid "physiological breathing sounds" refers to sound recorded from the patient as opposed to back ground electronic system noise and background room noise. Signal to Noise analysis (step 3) deals with calibration of system noise while the calibration of room noise against physiological noise is more complex due to the cast variety of possible room noise. "Physiological breathing sounds" refers to normal breathing sounds and various disordered breathing sounds such as snoring, wheezing, caughing, amongst others. Physiological breathing sounds may be, determined by comparing actual data (refer outputs marked A, B, C, D, F in Fig. 3) to prestored data that characterise various breathing and sleep disorders. The prestored data can be determined by comprehensive clinical trials.
Real-Time Breathe by breathe analysis (frequency and amplitude)
Breathe by breathe frequency analysis can be analysis classification of each breathing cycle in terms of amplitude, spectral and/or fast fourier transform data. These frequency and amplitude characteristics as determined for each breathing cycle (where each breathing cycle is detected in step 6 above) are then collated in terms of frequency and amplitude characterisation for each and every breathing cycle. By characterising each breathing cycle in this manner it is possible to provide a level of background noise discrimination (environmental and electronic system noise). This noise discrimination is possible as breathing noises can be related to the peak and trough points of the breathing cycle, for example. Background noise will not be associated with the breathing cycle as will physiological breathing noises. This is an example of how noise discrimination can be implemented within step 6.
Environmental sound Environmental noise is the total sound recorded minus the electronic signal noise and the physiological breathing sounds.
A "patient's sleep state" can be determined by the apparatus by simple means such as arousal detection. These arousal detections can be by way of monitoring additional channels such as movements from a special sensitive mattress. The mattress may be a piezo ceramic or capacitive discharge type. In both these aforementioned mattress types the apparatus is able to monitor the frequency, amplitude and regularity of patient body movements as an indicator as to whether or not the patient is likely to be asleep.
STEP 7
Step 7 represents tertiary processing capabilities of the apparatus. This includes a final analysis by referencing the information from step 6 (which determines valid physiological events as opposed to background and system noise- secondary analysis) and categorises the physiological event data into categories as recognised by medical physicians in the determination of a patients respiratory disorder or sleep disorder diagnosis.
This categorisation can include recognition of an apnea event. The latter is typically recognised by a lapse in breathing during a "patient's sleep state" for a period greater than 10 seconds. In the context of the present invention this could be recognised by detection of snoring sounds punctuated by relative breathing silence for 10 seconds or greater. This type of analysis and categorisation can provide a means of presenting a snoring index or number of snores per hour. The number of snores per hour is recognised by the medical user of the apparatus as an indicator that the patient is suffering from Obstructive Sleep Apnea for example.
By comparing the patient's current and context (ie the context of the current sound amplitude and frequency with respect to previous sound characteristics) sound amplitude and frequency characteristics with the reference data base characterising various breathing disorders, accurate classification of patient's respiratory disorder is possible. Common, but often under-diagnosed disorders such as asthma can be detected effectively with a simple representation of the present invention by allowing the sound analysis to detect wheezing as could be characteristic of asthma or asthma onset. Wheezing, for example, can be characterised by a pre-stored set of parameters which represent typical characteristics expected when a wheezing signal is detected. These typical wheezing parameters are determined by clinical studies. This technique of comparing a currently monitored patient signal characteristics with the signal characteristics from a range of typical parameters from a sample of respiratory disorders, assists the apparatus of the present invention to provide quick and accurate detection of a number of respiratory disorders with minimal channels required for monitoring (ie in the most common implementation of RACFSS, a simple microphone channel).
Step 7 also has the function of comparing each patient's breathing cycle with a data base of patient breathing characteristics. This data-base of breathing characteristics which may be derived from prior clinical studies, allows matching of frequency and amplitude characteristics of various breathing disorders. In this way a comparison of the current patient's frequency and amplitude characteristics with a known data base of characteristics and associated disorders may assist in accurate diagnosis of the patient's breathing disorders. For example, if the patient is wheezing, the frequency and amplitude characteristics of this sound analysis is likely to match with the reference data base for a diagnostic classification of wheezing, which together with other patient states may lead to the diagnosis of asthma. This diagnosis may lead to the delivery of ventilum. The output state or event in this case could be high level wheezing. In this example of wheezing RACFSS could be replaced with a ventilum delivery device as the feedback element. The application of ventilum to the patient as the feedback element to cancel out the acoustic symptom of wheezing manifests itself as a precise and accurate method of delivering the absolute minimum but highly responsive treatment of wheezing-related asthma.
The ventilum track algorithm could, for example (in a therapeutic mode of the apparatus) increase or decrease ventilum delivery to the patient until the wheezing state ceases. The optimum value of ventilum delivery could then be stored into a diagnostic ventilum set look-up-table (for later diagnostic reference by the supervising medical practitioner). Various values for ventilum delivery could therefore be determined in this way having regard to each patient state or breathing event.
STEP 8
Step 8 represents a capability of apparatus to store the monitored event type (ie snoring, wheezing, apnea), event time, event duration into hard disk, flash disk or other permanent or semi-permanent storage type.
This function may be optional because as noted above the apparatus can be configured with no or minimal permanent or semi-permanent storage capabilities in order to reduce the manufacturing cost of the apparatus. A review of this raw data allows a validation of the type of information monitored by the apparatus and also allows the apparatus to indicate to the user where and what events were detected. Thus the user of the system can validate the detection algorithms and processing capability of the apparatus, which is an important factor in the use of the apparatus for providing reliable patient diagnosis. STEP 9
Step 9 represents the system's RAM or other permanent storage facility which can be used to store various processing requirements of the apparatus, together with minimal data storage requirements such temporary storage of tertiary analysis results. Temporary storage can be suitable for the purpose of providing to the user of the apparatus, a means of having a summary of the patient diagnosis. This diagnosis in the simplest form could be, for example, a snoring index (eg. snores per hour).
STEP 10
Step 10 provides "Stop Record" mode. This is achieved by detecting whether the system has a valid pre-programmed stop time, whether the system has been selected for off or whether the system power has been switched off.
STEP 11
Step 11 ends the process and follows step 10 system off selection.
A flow diagram associated with operation of Block 3 (respiratory acoustic cancellation feedback servo system - RACFSS) in Fig. 2 is shown in Figs. 4 and 4A. With reference to Figs. 4 and 4A, the following is a description of the steps associated with Block 3.
STEP 1
Step 1 represents the system start which could be operated by selecting power on, the pre-prog ramming of a particular start-time, by applying power to the apparatus or alternatively by remote start command. STEP 2
Step 1 represents the function of the device which detects the system user's selection of therapeutic mode. The selection of therapeutic mode is optional and allows the system to provide control for a gas delivery device, while at the same time providing detection and monitoring of respiratory disorders. The therapeutic function may not be required where the apparatus is to be used as an indicator of snoring or apnea but would be required where the apparatus is to be used for the purpose of monitoring sound while at the same time providing gas delivery control utilising the acoustic cancellation capabilities of the apparatus.
STEP 3
Step 3 analyses input data including microphone input data. The input data is analysed by reviewing the primary, secondary and tertiary results as detailed in the flow diagram of figure 3.
It is necessary to determine whether an event such as snoring has commenced in order to prepare the apparatus to operate in RACFSS mode.
STEP 4
Step 4 decides whether a respiratory event or the start of a respiratory event is detected. The apparatus will prepare itself to track the signal amplitude detected from a respiratory event in order to be able to produce a control signal for the purpose of physiological event cancellation by way of gas delivery.
STEP 5
Step 5 produces the control signal for the purpose of providing an appropriate base level pressure and modulated pressure. This control signal contains both a base level or low frequency pressure or airflow control and a higher frequency modulated pressure or airflow control. The apparatus produces the control signal for controlling an external device. Alternatively the apparatus could be integrated into a gas delivery device which provides the capability to regulate the pressure or airflow to a patients face mask (ie nasal or full mask).
This pressure control can be similar in frequency and opposite in phase to the original acoustic waves as detected by the microphone. The apparatus should have sufficient processing capability to produce this opposite phase air flow modulation together with a base pressure in order to cancel out physiological events such as snoring with a minimum pressure applied to the patient (ie by way of nasal mask). It is desirable to keep the delivery of pressure to the patient at a minimum in order to minimise the discomfort to the patient and also to minimise side effects from therapeutic intervention by way of gas delivery.
The apparatus of the present invention is unique in its ability to produce a servo loop effect in the application of patient gas delivery. By modulating and controlling the base pressure delivery to minimise the sound monitored during snoring episodes (due to the patient's vibrating upper palette), the apparatus may apply a precise amount of opposite phase modulated pressure to stabilise the vibrating upper palette. The apparatus can provide the combination of base pressure and modulated pressure waveforms by utilising conventional technology to produce a continuous or slowly varying (low frequency) gas delivery - such as a range of pressure (say 0 CMH20 to 20 CMH20 range) with variation of rate of pressure or airflow change from say continuous to 10 cycles per second. At the same time the apparatus may provide a higher frequency modulated gas delivery - such as a range of pressure (say 0 CMH20 to 3 CMH20 range) with variation of rate of pressure or airflow change from say .5 cycles per second to say 1000 cycles per second. The apparatus of the present invention may provide these two forms of gas delivery, being continuous and higher frequency gas modulation. In one form the latter may be provided by means of a diaphragm (similar to the cone of the driver of an audio loudspeaker) to modulate the low frequency or continuous gas delivery obtainable from a conventional respiratory ventilator or air delivery blower device. One example of the manner in which a continuous gas delivery system may be modified in accordance with the principles of the present invention is described below with reference to Fig. 5.
STEP 6
High frequency pressure rate changes and low frequency base pressure changes may be continuously checked by the system control so as not to exceed preprogrammed patient safety limits. These pressure limits may be detected and checked by way of two methods;
1) System control may limit the amount of base pressure and modulation control output from the system in order to not exceed preset patient limits. 2) The apparatus may monitor gas delivery to the patient by way of a pressure or airflow sensor interfaced to the patients breathing. This interface can be by way of a sensor attached to the patient's breathing mask, for example. The monitored airflow or pressure may be limited by the apparatus to fall within safe patient limits as reprogrammed by the system or the system user (supervising medical practitioner).
STEP 7
Step 7 functions to correct any excessive pressure or airflow modulation to remain within safe patient limits.
STEP 8
Step 8 compares microphone signal's current data with the microphone signal's previous data and determines through processes of comparing alignment and subtraction, whether activated pressure changes are having an effect on the amplitude of the respiratory event. That is, is the effect of pressure activation change causing the current respiratory event (ie snoring sound) to reduce in presence as measured by a decrease in the amplitude of the sound signal. Reference may be had to the example waveforms shown in Figures 1A to 1 F.
STEP 9
Step 9 determines whether pressure or airflow change activation reduce the effect of the respiratory event, ie does snoring subside.
The purpose of this step is to determine whether or not the application of a change of pressure and airflow to the patient is directly related to reducing the symptoms of the patient's respiratory disorder.
STEP 10
Has system "Stop Record" mode or has system pre-programmed stop time been selected or has system power been interrupted or switched off ?
STEP 11
Step 11 ends the process and follows step 10 system off selection.
* * *
Fig. 5 shows one example whereby a continuous gas delivery system can be modified in accordance with the principles of the present invention. Modification is by means of a T section element 50 inserted into the supply of base or continuous pressure or airflow 51 associated with the system. The modification comprises an air pressure modulator 52 (refer module 6 in Fig. 1) placed in communication with the leg of T section element 50 such that air pressure changes produced by modulator 52 are impressed upon the base or continuous pressure or airflow 51 to form a composite pressure/air flow 53. Composite flow 53 comprises a combination of base pressure 51 and modulated pressure/airflow produced via modulator 52. The air pressure changes impressed via modulator 52 are generally of a substantially higher frequency than changes that may be produced by the continuous gas delivery system.
Finally, it is to be understood that various alterations, modifications and/or additions may be introduced into the constructions and arrangements of parts previously described without departing from the spirit or ambit of the invention.

Claims

1. Apparatus for controlling gas delivery to a patient, said delivery being adapted to maintain effective respiratory function, said apparatus including: means for monitoring one or more physiological variables associated with said patient; means for deriving from said one or more variables, data representing a respiratory state associated with said patient; and means for determining from said data, a gas pressure value which substantially prevents a deterioration in said state.
2. Apparatus according to claim 1 wherein said physiological variables include breathing airflow and/or sound.
3. Apparatus according to claim 2 wherein said determining means includes an algorithm adapted to generate a gas pressure signal which is substantially 180┬░ out of phase relative to the phase of said patient breathing and/or sound.
4. Apparatus according to claim 2 wherein said gas pressure value includes a modulated component.
5. Apparatus according to claim 4 wherein said modulated component is of opposite acoustic phase to said patient breathing and/or sound.
6. Apparatus according to claim 4 or 5 wherein said modulated component is adapted to acoustically cancell vibration in the patient's upper palette.
7. Apparatus according to any one of claims 4 to 6 wherein said gas pressure value includes a substantially continuous component and/or a component which changes relatively slowly when compared to said modulated component.
8. Apparatus according to any one of the preceding claims wherein said physiological variables include one or more of brainwaves, heart beat, muscle function and/or patient position.
9. Apparatus according to any one of the preceding claims wherein at least one of said means for deriving and said means for determining is provided via digital processing means.
10. Apparatus according to any one of the preceding claims wherein said deriving means includes an algorithm.
11. Apparatus according to any one of the preceeding claims wherein said deriving means includes means for evaluating sleep and/or arousal states.
12. Apparatus according to any one of the preceeding claims wherein said deriving means includes means for detecting micro arousals.
13. Apparatus according to any one of the preceeding claims wherein said deriving means includes means for detecting respiratory events.
14. Apparatus according to any one of the preceeding claims including a gas delivery means for delivering gas to said patient in accordance with said determined gas pressure.
15. Apparatus according to claim 11 wherein said gas delivery means include a gas pressure valve.
16. Apparatus according to claim 11 wherein said gas delivery means includes an acoustic transducer such as a loudspeaker driver.
17. Apparatus according to any one of the preceeding claims including means for delivering a drug such as ventilum to said patient.
18. Apparatus for controlling drug delivery to a patient, said delivery being adapted to maintain effective respiratory function, said apparatus including: means for monitoring one or more physiological variables associated with said patient; means for deriving from said one or more variables, data representing a respiratory state associated with said patient; and means for determining from said data, a drug quantity which substantially prevents a deterioration in said state.
19. Apparatus according to claim 18 wherein said physiological variables include breathing airflow and/or sound.
20. Apparatus according to claim 18 or 19 wherein said drug includes ventilum.
21. A method for controlling gas delivery to a patient, said delivery being adapted to maintain effective respiratory function, said method including the steps of: monitoring one or more physiological variables associated with said patient; deriving from said one or more variables, data representing a respiratory state associated with said patient; and determining from said data, a gas pressure value which substantially prevents a deterioration in said state.
22. A method according to claim 21 wherein said physiological variables include breathing airflow and/or sound.
23. A method according to claim 22 wherein said determining step includes an algorithm adapted to generate a gas pressure signal which is substantially 180┬░ out of phase relative to the phase of said patient breathing and/or sound.
24. A method according to claim 22 wherein said gas pressure value includes a modulated component.
25. A method according to claim 24 wherein said modulated component is of opposite acoustic phase to said patient breathing and/or sound.
26. A method according to claim 24 or 25 wherein said modulated component is adapted to acoustically cancell vibration in the patient's upper palette.
27. A method according to any one of the preceding claims wherein said gas pressure value include a substantially continuous component.
28. A method according to any one of claims 21 to 27 wherein said physiological variables include one or more of brainwaves, heart beat, muscle function and/or patient position.
29. Apparatus for controlling gas delivery to a patient substantially as herein described with reference to the accompanying drawings.
30. A method for controlling gas delivery to a patient substantially as herein described with reference to the accompanying drawings.
PCT/AU1997/000278 1997-05-07 1997-05-07 Controlling gas or drug delivery to patient WO1998050095A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AU26269/97A AU741637B2 (en) 1997-05-07 1997-05-07 Controlling gas or drug delivery to patient
CNB971821534A CN1154521C (en) 1997-05-07 1997-05-07 Controlling gas or drug delivery to patient
EP97917938A EP1007125B1 (en) 1997-05-07 1997-05-07 Device for controlling gas or drug delivery to patient
RU99125607/14A RU2197281C2 (en) 1997-05-07 1997-05-07 Device for controlling gas or medicament supply to a patient
IL13274897A IL132748A (en) 1997-05-07 1997-05-07 Apparatus and method for controlling gas or drug delivery to a patient
PCT/AU1997/000278 WO1998050095A1 (en) 1997-05-07 1997-05-07 Controlling gas or drug delivery to patient
DE69730748T DE69730748T2 (en) 1997-05-07 1997-05-07 DEVICE FOR CONTROLLING GAS OR MEDICINE ADMINISTRATION TO A PATIENT
JP54753098A JP4090079B2 (en) 1997-05-07 1997-05-07 Control of gas or drug delivery to the patient
KR10-1999-7010281A KR100454157B1 (en) 1997-05-07 1997-05-07 Apparatus for controlling gas delivery to patient
AT97917938T ATE276001T1 (en) 1997-05-07 1997-05-07 DEVICE FOR CONTROLLING GAS OR DRUG ADMINISTRATION TO A PATIENT
US09/423,380 US6431171B1 (en) 1997-05-07 1997-05-07 Controlliing gas or drug delivery to patient

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB971821534A CN1154521C (en) 1997-05-07 1997-05-07 Controlling gas or drug delivery to patient
PCT/AU1997/000278 WO1998050095A1 (en) 1997-05-07 1997-05-07 Controlling gas or drug delivery to patient

Publications (1)

Publication Number Publication Date
WO1998050095A1 true WO1998050095A1 (en) 1998-11-12

Family

ID=3764337

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1997/000278 WO1998050095A1 (en) 1997-05-07 1997-05-07 Controlling gas or drug delivery to patient

Country Status (9)

Country Link
US (1) US6431171B1 (en)
JP (1) JP4090079B2 (en)
KR (1) KR100454157B1 (en)
AT (1) ATE276001T1 (en)
AU (1) AU741637B2 (en)
DE (1) DE69730748T2 (en)
IL (1) IL132748A (en)
RU (1) RU2197281C2 (en)
WO (1) WO1998050095A1 (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6349724B1 (en) 2000-07-05 2002-02-26 Compumedics Sleep Pty. Ltd. Dual-pressure blower for positive air pressure device
WO2002039366A1 (en) * 2000-11-13 2002-05-16 Siemens Medical Solutions Usa, Inc. A system and method for processing ventilator information
WO2002041135A2 (en) * 2000-11-17 2002-05-23 Siemens Medical Solutions Usa, Inc. A system and method for processing patient information
WO2001083007A3 (en) * 2000-05-03 2002-05-30 Aspect Medical Systems Inc System and method for adaptive drug delivery
EP1120124A3 (en) * 2000-01-25 2003-04-02 Siemens-Elema AB Ventilator
US6832609B2 (en) * 2000-12-11 2004-12-21 Resmed Limited Methods and apparatus for stroke patient treatment
EP1551286A2 (en) * 2002-10-09 2005-07-13 Compumedics Limited Method and apparatus for maintaining and monitoring sleep quality during therapeutic treatments
WO2005072792A1 (en) * 2004-01-27 2005-08-11 Aspect Medical Systems, Inc. System for adaptive drug delivery
US7165547B2 (en) * 1999-09-24 2007-01-23 Ric Investments, Llc Apparatus and method for providing high frequency variable pressure to a patient
DE102004011078B4 (en) * 2004-03-06 2007-11-15 Golden, Eduard, Dr. Respiratory Equipment
JP2011200658A (en) * 1999-09-15 2011-10-13 Resmed Ltd Ventilatory assistance using external effort sensor
GB2479953A (en) * 2010-04-26 2011-11-02 Sagentia Ltd Drug delivery device with a microphone and processing circuitry
US9008761B2 (en) 2010-02-01 2015-04-14 Proteus Digital Health, Inc. Two-wrist data gathering system
US9014779B2 (en) 2010-02-01 2015-04-21 Proteus Digital Health, Inc. Data gathering system
US9084566B2 (en) 2006-07-07 2015-07-21 Proteus Digital Health, Inc. Smart parenteral administration system
US9125979B2 (en) 2007-10-25 2015-09-08 Proteus Digital Health, Inc. Fluid transfer port information system
WO2015144442A1 (en) * 2014-03-25 2015-10-01 Koninklijke Philips N.V. Inhaler with two microphones for detection of inhalation flow
US9757045B2 (en) 2004-01-27 2017-09-12 Universiteit Gent System and method for adaptive drug delivery

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070000494A1 (en) * 1999-06-30 2007-01-04 Banner Michael J Ventilator monitor system and method of using same
US6968294B2 (en) * 2001-03-15 2005-11-22 Koninklijke Philips Electronics N.V. Automatic system for monitoring person requiring care and his/her caretaker
DE10230165A1 (en) 2002-07-04 2004-01-15 Ino Therapeutics Gmbh Method and device for the administration of carbon monoxide
US7367339B2 (en) * 2002-10-03 2008-05-06 Scott Laboratories, Inc. Neural networks in sedation and analgesia systems
KR20050072435A (en) * 2002-10-09 2005-07-11 컴퓨메딕스 리미티드 Method and apparatus for maintaining and monitoring sleep quality during therapeutic treatments
US7189204B2 (en) 2002-12-04 2007-03-13 Cardiac Pacemakers, Inc. Sleep detection using an adjustable threshold
US7887493B2 (en) 2003-09-18 2011-02-15 Cardiac Pacemakers, Inc. Implantable device employing movement sensing for detecting sleep-related disorders
US7668591B2 (en) 2003-09-18 2010-02-23 Cardiac Pacemakers, Inc. Automatic activation of medical processes
US8251061B2 (en) 2003-09-18 2012-08-28 Cardiac Pacemakers, Inc. Methods and systems for control of gas therapy
US7967756B2 (en) 2003-09-18 2011-06-28 Cardiac Pacemakers, Inc. Respiratory therapy control based on cardiac cycle
ATE413902T1 (en) 2003-08-18 2008-11-15 Cardiac Pacemakers Inc PATIENT MONITORING SYSTEM
US7662101B2 (en) 2003-09-18 2010-02-16 Cardiac Pacemakers, Inc. Therapy control based on cardiopulmonary status
US7396333B2 (en) 2003-08-18 2008-07-08 Cardiac Pacemakers, Inc. Prediction of disordered breathing
US8002553B2 (en) 2003-08-18 2011-08-23 Cardiac Pacemakers, Inc. Sleep quality data collection and evaluation
US7357136B2 (en) 2003-08-18 2008-04-15 Ric Investments, Llc Patient interface assembly and system using same
US8606356B2 (en) 2003-09-18 2013-12-10 Cardiac Pacemakers, Inc. Autonomic arousal detection system and method
US8361013B2 (en) 2004-04-19 2013-01-29 The Invention Science Fund I, Llc Telescoping perfusion management system
US7850676B2 (en) 2004-04-19 2010-12-14 The Invention Science Fund I, Llc System with a reservoir for perfusion management
US8337482B2 (en) 2004-04-19 2012-12-25 The Invention Science Fund I, Llc System for perfusion management
US8353896B2 (en) 2004-04-19 2013-01-15 The Invention Science Fund I, Llc Controllable release nasal system
US8512219B2 (en) 2004-04-19 2013-08-20 The Invention Science Fund I, Llc Bioelectromagnetic interface system
US9011329B2 (en) 2004-04-19 2015-04-21 Searete Llc Lumenally-active device
US7575005B2 (en) * 2004-05-18 2009-08-18 Excel-Tech Ltd. Mask assembly with integrated sensors
US8244340B2 (en) * 2006-12-22 2012-08-14 Natus Medical Incorporated Method, system and device for sleep stage determination using frontal electrodes
US20070208269A1 (en) * 2004-05-18 2007-09-06 Mumford John R Mask assembly, system and method for determining the occurrence of respiratory events using frontal electrode array
US20060258930A1 (en) * 2004-05-18 2006-11-16 Jianping Wu Device for use in sleep stage determination using frontal electrodes
WO2006043278A1 (en) * 2004-10-20 2006-04-27 Deepbreeze Ltd. Method and system for managing mechanical respiratory ventilation
US7680534B2 (en) 2005-02-28 2010-03-16 Cardiac Pacemakers, Inc. Implantable cardiac device with dyspnea measurement
US8545416B1 (en) * 2005-11-04 2013-10-01 Cleveland Medical Devices Inc. Integrated diagnostic and therapeutic system and method for improving treatment of subject with complex and central sleep apnea
US7942824B1 (en) 2005-11-04 2011-05-17 Cleveland Medical Devices Inc. Integrated sleep diagnostic and therapeutic system and method
US8172766B1 (en) * 2005-11-04 2012-05-08 Cleveland Medical Devices Inc. Integrated sleep diagnosis and treatment device and method
EP2630914B1 (en) * 2006-01-06 2017-09-13 ResMed Limited Computer controlled CPAP system with snore detection
US20070249951A1 (en) * 2006-04-19 2007-10-25 The Research Foundation Of State University Of New York Apparatus, System and Method for Assessing Alveolar Inflation
US7845350B1 (en) 2006-08-03 2010-12-07 Cleveland Medical Devices Inc. Automatic continuous positive airway pressure treatment system with fast respiratory response
US8728059B2 (en) 2006-09-29 2014-05-20 Covidien Lp System and method for assuring validity of monitoring parameter in combination with a therapeutic device
NZ548290A (en) * 2006-12-30 2009-09-25 Safer Sleep Ltd Notification system
KR100854062B1 (en) * 2007-01-17 2008-08-26 바이오슬립메드 주식회사 Apparatus for preventing from snoring and method using the same
DE102007031017B3 (en) * 2007-07-04 2009-02-12 Dräger Medical AG & Co. KG Method for operating an anesthetic or respiratory device with trigger function and device for this purpose
CO6030034A1 (en) * 2007-08-16 2009-04-30 Fundacion Cardiovascular De Co MOBILE MONITORING, SURVEILLANCE AND VITAL SUPPORT SYSTEM FOR PATIENT CARE IN INTENSIVE CARE
US8419638B2 (en) 2007-11-19 2013-04-16 Proteus Digital Health, Inc. Body-associated fluid transport structure evaluation devices
WO2009103111A1 (en) * 2008-02-19 2009-08-27 Charles Rupert Russell-Smith Patient's breathing detection and monitoring
WO2009119449A1 (en) * 2008-03-26 2009-10-01 国立大学法人 九州工業大学 Tracheal tube maintenance and management system
US8251876B2 (en) 2008-04-22 2012-08-28 Hill-Rom Services, Inc. Breathing exercise apparatus
US20090320836A1 (en) * 2008-06-30 2009-12-31 Baker Jr Clark R Method For Regulating Treatment Based On A Medical Device Under Closed-Loop Physiologic Control
US20100163039A1 (en) 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for administering an inhalable compound
JP2012513807A (en) * 2008-12-30 2012-06-21 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ System, method and respiratory device for supporting a subject's airway
US20100163036A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
WO2010080709A1 (en) * 2009-01-08 2010-07-15 Hancock Medical Self-contained, intermittent positive airway pressure systems and methods for treating sleep apnea, snoring, and other respiratory disorders
US20100288283A1 (en) * 2009-05-15 2010-11-18 Nellcor Puritan Bennett Llc Dynamic adjustment of tube compensation factor based on internal changes in breathing tube
EP2263620A1 (en) * 2009-06-16 2010-12-22 Koninklijke Philips Electronics N.V. Snoring reduction apparatus
US8336546B2 (en) 2011-02-08 2012-12-25 Hancock Medical, Inc. Positive airway pressure system with head control
EP2535000A1 (en) * 2011-06-17 2012-12-19 Technische Universität München Method and system for quantifying anaesthesia or a state of vigilance
WO2013068933A1 (en) * 2011-11-07 2013-05-16 Koninklijke Philips Electronics N.V. Automatic patient synchrony adjustment for non invasive ventilation
US9180271B2 (en) 2012-03-05 2015-11-10 Hill-Rom Services Pte. Ltd. Respiratory therapy device having standard and oscillatory PEP with nebulizer
US9327089B2 (en) 2012-03-30 2016-05-03 Covidien Lp Methods and systems for compensation of tubing related loss effects
US9295803B2 (en) * 2012-08-31 2016-03-29 General Electric Company Ventilator sychronization indicator
CN104717995B (en) * 2012-10-10 2017-12-29 皇家飞利浦有限公司 Compensated using the adaptive patient circuit of the pressure sensor at mask device
US10314989B2 (en) 2013-01-28 2019-06-11 Hancock Medical, Inc. Position control devices and methods for use with positive airway pressure systems
JP6656789B2 (en) * 2013-10-29 2020-03-04 パイオニア株式会社 Signal processing apparatus and method
WO2016028525A1 (en) 2014-08-18 2016-02-25 Hancock Medical, Inc. Portable pap device with humidification
USD776802S1 (en) 2015-03-06 2017-01-17 Hancock Medical, Inc. Positive airway pressure system console
EP4186548A1 (en) 2015-04-02 2023-05-31 Hill-Rom Services PTE. LTD. Mask leakage detection for a respiratory device
CN109310348B (en) 2016-05-19 2022-01-25 汉考克医药公司 Posture obstructive sleep apnea detection system
CN114901133A (en) * 2019-10-31 2022-08-12 瑞思迈私人有限公司 System and method for active noise cancellation

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011054A1 (en) * 1990-12-21 1992-07-09 Puritan-Bennett Corporation Inspiratory airway pressure system
WO1992022244A1 (en) * 1991-06-14 1992-12-23 Respironics, Inc. Method and apparatus for controlling sleep disorder breathing
US5199424A (en) * 1987-06-26 1993-04-06 Sullivan Colin E Device for monitoring breathing during sleep and control of CPAP treatment that is patient controlled
WO1993009834A1 (en) * 1991-11-14 1993-05-27 University Technologies International Inc. Auto cpap system
WO1993021982A1 (en) * 1992-05-07 1993-11-11 New York University Apnea treatment using adjustable positive airway pressure
US5353788A (en) * 1992-09-21 1994-10-11 Miles Laughton E Cardio-respiratory control and monitoring system for determining CPAP pressure for apnea treatment
WO1994023780A1 (en) * 1993-04-15 1994-10-27 Respironics, Inc. Method and apparatus for controlling sleep disorder breathing
US5444786A (en) * 1993-02-09 1995-08-22 Snap Laboratories L.L.C. Snoring suppression system
US5490502A (en) * 1992-05-07 1996-02-13 New York University Method and apparatus for optimizing the continuous positive airway pressure for treating obstructive sleep apnea
US5551419A (en) * 1994-12-15 1996-09-03 Devilbiss Health Care, Inc. Control for CPAP apparatus
WO1996040335A1 (en) * 1995-06-07 1996-12-19 Respironics, Inc. Sleep apnea treatment apparatus and humidifier
US5617846A (en) * 1994-09-08 1997-04-08 Gottlieb Weinmann Gerate Fur Medizin Und Arbeitsschutz Gmbh & Co. Method of controlling a respirator for treatment of sleep apnea and device for carrying out the method

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5948106B2 (en) 1980-08-27 1984-11-24 株式会社東芝 respiratory monitoring device
WO1988001010A1 (en) 1986-07-30 1988-02-11 Great Lakes Chemical Corporation Calcium-free clear high density fluids
US5047930A (en) 1987-06-26 1991-09-10 Nicolet Instrument Corporation Method and system for analysis of long term physiological polygraphic recordings
US5522382A (en) * 1987-06-26 1996-06-04 Rescare Limited Device and method for treating obstructed breathing having a delay/ramp feature
JPS6487934A (en) * 1987-09-30 1989-04-03 Yaskawa Denki Seisakusho Kk Vibration damping method and device
US5845636A (en) 1989-05-19 1998-12-08 Puritan Bennett Corporation Method and apparatus for maintaining patient airway patency
US5259373A (en) 1989-05-19 1993-11-09 Puritan-Bennett Corporation Inspiratory airway pressure system controlled by the detection and analysis of patient airway sounds
AU638479B2 (en) 1989-07-20 1993-07-01 E.I. Du Pont De Nemours And Company Improved process for preparing bafbr:eu phosphors
US5239995A (en) 1989-09-22 1993-08-31 Respironics, Inc. Sleep apnea treatment apparatus
US5148802B1 (en) 1989-09-22 1997-08-12 Respironics Inc Method and apparatus for maintaining airway patency to treat sleep apnea and other disorders
US6085747A (en) * 1991-06-14 2000-07-11 Respironics, Inc. Method and apparatus for controlling sleep disorder breathing
US5188098A (en) 1991-11-04 1993-02-23 The Trustees Of The University Of Pennsylvania Method and apparatus for ECG gated ventilation
US5520192A (en) 1991-12-23 1996-05-28 Imperial College Of Science, Technology And Medicine Apparatus for the monitoring and control of respiration
US5590648A (en) * 1992-11-30 1997-01-07 Tremont Medical Personal health care system
FR2700683B1 (en) 1993-01-28 1995-04-14 Univ Rennes Sleep phase recognition device, and corresponding application.
JP2979879B2 (en) * 1993-02-16 1999-11-15 松下電器産業株式会社 Bed equipment
JPH0728476A (en) * 1993-06-24 1995-01-31 Sekisui Chem Co Ltd Muffler device
US5464012A (en) 1993-09-13 1995-11-07 Hewlett-Packard Company Patient alarm detection using target mode
DE69433729T2 (en) 1993-11-05 2005-04-28 Resmed Ltd., North Ryde Sensor for apnea
SE508285C2 (en) 1994-06-07 1998-09-21 Biosys Ab Method and apparatus for assessing wakefulness and drowsiness at various stages between wakefulness and sleep in a way that is not monitored non-interfering
JPH0880285A (en) * 1994-09-14 1996-03-26 Matsushita Electric Ind Co Ltd Monitor
US5485851A (en) 1994-09-21 1996-01-23 Medtronic, Inc. Method and apparatus for arousal detection
JPH08299050A (en) * 1995-05-10 1996-11-19 Brother Ind Ltd Silenced drier
US5647846A (en) * 1995-05-17 1997-07-15 Scimed Life Systems, Inc. Catheter having geometrically shaped surface and method of manufacture
US6000396A (en) 1995-08-17 1999-12-14 University Of Florida Hybrid microprocessor controlled ventilator unit
US5953713A (en) 1995-10-26 1999-09-14 Board Of Regents, The University Of Texas System Method and apparatus for treatment of sleep disorder breathing employing artificial neural network
US6123072A (en) * 1996-09-11 2000-09-26 Downs; John B. Method and apparatus for breathing during anesthesia
AUPO418696A0 (en) * 1996-12-12 1997-01-16 Resmed Limited A substance delivery apparatus

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5199424A (en) * 1987-06-26 1993-04-06 Sullivan Colin E Device for monitoring breathing during sleep and control of CPAP treatment that is patient controlled
WO1992011054A1 (en) * 1990-12-21 1992-07-09 Puritan-Bennett Corporation Inspiratory airway pressure system
WO1992022244A1 (en) * 1991-06-14 1992-12-23 Respironics, Inc. Method and apparatus for controlling sleep disorder breathing
WO1993009834A1 (en) * 1991-11-14 1993-05-27 University Technologies International Inc. Auto cpap system
WO1993021982A1 (en) * 1992-05-07 1993-11-11 New York University Apnea treatment using adjustable positive airway pressure
US5490502A (en) * 1992-05-07 1996-02-13 New York University Method and apparatus for optimizing the continuous positive airway pressure for treating obstructive sleep apnea
US5353788A (en) * 1992-09-21 1994-10-11 Miles Laughton E Cardio-respiratory control and monitoring system for determining CPAP pressure for apnea treatment
US5444786A (en) * 1993-02-09 1995-08-22 Snap Laboratories L.L.C. Snoring suppression system
WO1994023780A1 (en) * 1993-04-15 1994-10-27 Respironics, Inc. Method and apparatus for controlling sleep disorder breathing
US5617846A (en) * 1994-09-08 1997-04-08 Gottlieb Weinmann Gerate Fur Medizin Und Arbeitsschutz Gmbh & Co. Method of controlling a respirator for treatment of sleep apnea and device for carrying out the method
US5551419A (en) * 1994-12-15 1996-09-03 Devilbiss Health Care, Inc. Control for CPAP apparatus
WO1996040335A1 (en) * 1995-06-07 1996-12-19 Respironics, Inc. Sleep apnea treatment apparatus and humidifier

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011200658A (en) * 1999-09-15 2011-10-13 Resmed Ltd Ventilatory assistance using external effort sensor
US7165547B2 (en) * 1999-09-24 2007-01-23 Ric Investments, Llc Apparatus and method for providing high frequency variable pressure to a patient
EP1120124A3 (en) * 2000-01-25 2003-04-02 Siemens-Elema AB Ventilator
US6601583B2 (en) 2000-01-25 2003-08-05 Siemens Elema Ab Ventilator wherein operation is modifiable dependent on patient sounds
WO2001083007A3 (en) * 2000-05-03 2002-05-30 Aspect Medical Systems Inc System and method for adaptive drug delivery
US6599281B1 (en) 2000-05-03 2003-07-29 Aspect Medical Systems, Inc. System and method for adaptive drug delivery
US6605072B2 (en) 2000-05-03 2003-08-12 Aspect Medical Systems, Inc. System and method for adaptive drug delivery
US7220240B2 (en) 2000-05-03 2007-05-22 Aspect Medical Systems, Inc. System and method for adaptive drug delivery
EP1278564B2 (en) 2000-05-03 2013-11-20 Universiteit Gent System for adaptive drug delivery
US6349724B1 (en) 2000-07-05 2002-02-26 Compumedics Sleep Pty. Ltd. Dual-pressure blower for positive air pressure device
WO2002039366A1 (en) * 2000-11-13 2002-05-16 Siemens Medical Solutions Usa, Inc. A system and method for processing ventilator information
WO2002041135A3 (en) * 2000-11-17 2003-12-04 Siemens Medical Solutions A system and method for processing patient information
US7590551B2 (en) 2000-11-17 2009-09-15 Draeger Medical Systems, Inc. System and method for processing patient information
WO2002041135A2 (en) * 2000-11-17 2002-05-23 Siemens Medical Solutions Usa, Inc. A system and method for processing patient information
US7018341B2 (en) 2000-12-11 2006-03-28 Resmed Limited Methods and apparatus for stroke patient treatment
US6832609B2 (en) * 2000-12-11 2004-12-21 Resmed Limited Methods and apparatus for stroke patient treatment
US7942823B2 (en) 2000-12-11 2011-05-17 Resmed Limited Methods and apparatus for stroke patient treatment
AU2003277338B2 (en) * 2002-10-09 2008-06-05 Compumedics Limited Method and apparatus for maintaining and monitoring sleep quality during therapeutic treatments
EP1551286A4 (en) * 2002-10-09 2009-06-24 Compumedics Ltd Method and apparatus for maintaining and monitoring sleep quality during therapeutic treatments
EP1551286A2 (en) * 2002-10-09 2005-07-13 Compumedics Limited Method and apparatus for maintaining and monitoring sleep quality during therapeutic treatments
US9757045B2 (en) 2004-01-27 2017-09-12 Universiteit Gent System and method for adaptive drug delivery
AU2005209275B2 (en) * 2004-01-27 2011-05-26 Fresenius Vial Sas System for adaptive drug delivery
WO2005072792A1 (en) * 2004-01-27 2005-08-11 Aspect Medical Systems, Inc. System for adaptive drug delivery
DE102004011078B4 (en) * 2004-03-06 2007-11-15 Golden, Eduard, Dr. Respiratory Equipment
US9084566B2 (en) 2006-07-07 2015-07-21 Proteus Digital Health, Inc. Smart parenteral administration system
US9125979B2 (en) 2007-10-25 2015-09-08 Proteus Digital Health, Inc. Fluid transfer port information system
US9008761B2 (en) 2010-02-01 2015-04-14 Proteus Digital Health, Inc. Two-wrist data gathering system
US9014779B2 (en) 2010-02-01 2015-04-21 Proteus Digital Health, Inc. Data gathering system
US10376218B2 (en) 2010-02-01 2019-08-13 Proteus Digital Health, Inc. Data gathering system
GB2479953A (en) * 2010-04-26 2011-11-02 Sagentia Ltd Drug delivery device with a microphone and processing circuitry
GB2479953B (en) * 2010-04-26 2015-04-29 Sagentia Ltd Drug delivery device
WO2015144442A1 (en) * 2014-03-25 2015-10-01 Koninklijke Philips N.V. Inhaler with two microphones for detection of inhalation flow
RU2664624C2 (en) * 2014-03-25 2018-08-21 Конинклейке Филипс Н.В. Inhaler with two microphones for detection of inhalation flow
US10456536B2 (en) 2014-03-25 2019-10-29 Koninklijke Philips N.V. Inhaler with two microphones for detection of inhalation flow

Also Published As

Publication number Publication date
IL132748A0 (en) 2001-03-19
DE69730748D1 (en) 2004-10-21
JP2001523136A (en) 2001-11-20
KR100454157B1 (en) 2004-10-26
US6431171B1 (en) 2002-08-13
RU2197281C2 (en) 2003-01-27
ATE276001T1 (en) 2004-10-15
JP4090079B2 (en) 2008-05-28
KR20010012329A (en) 2001-02-15
IL132748A (en) 2003-11-23
AU741637B2 (en) 2001-12-06
AU2626997A (en) 1998-11-27
DE69730748T2 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
AU741637B2 (en) Controlling gas or drug delivery to patient
US6398739B1 (en) Device and method for nonclinical monitoring of breathing during sleep, control of CPAP treatment and preventing apnea
US7004908B2 (en) Method and apparatus useful in the diagnosis of obstructive sleep apnea of a patient
EP0833586B1 (en) Device for detecting and recording snoring
KR101060923B1 (en) Method and Apparatus for Maintaining and Monitoring Sleep Quality During Therapeutic Treatments
US20120184825A1 (en) Method for detecting and analyzing sleep-related apnea, hypopnea, body movements, and snoring with non-contact device
US20090107498A1 (en) Respiratory Equipment and Method for Controlling Respiratory Equipment
WO1988010108A1 (en) Device for monitoring breathing during sleep and control of cpap treatment
EP0862475A1 (en) Apparatus for gas delivery
AU2005251726A1 (en) System and method for automated titration of continuous positive airway pressure
EP1007125B1 (en) Device for controlling gas or drug delivery to patient
WO2001015602A1 (en) System and method for the diagnosis of respiratory disorders
Xinyue et al. Breathing detection from tracheal sounds in both temporal and frequency domains in the context of phrenic nerve stimulation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1199901046

Country of ref document: VN

Ref document number: 97182153.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 1998 547530

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09423380

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1019997010281

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1997917938

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997917938

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWP Wipo information: published in national office

Ref document number: 1019997010281

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1019997010281

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1997917938

Country of ref document: EP